Press Releases

Total revenue of $126.7 million , including net product sales of $89.7 million for Trokendi XR®, $23.7 million for Oxtellar XR®, and $10.6 million for the acquired Parkinson’s disease (PD) products Operating earnings of $45.5 million Completed acquisition of CNS portfolio of US WorldMeds on June 9,
Posted: August 18, 2020
Second quarter total revenue is estimated to be $126.7 million , a 21% increase over 2019 Net product sales of Trokendi XR® and Oxtellar XR® are estimated to be $113.4 million , an 11% increase over 2019 Completed acquisition of CNS portfolio of US WorldMeds on June 9, 2020 Management to host a
Posted: August 11, 2020
Displaying 1 - 10 of 21